Wound dressing assembly including (i) blood-clotting mold device having an enclosure defined between walls of a main body and a removable closure over an opening and configured for introduction of blood thereinto, and (ii) coagulation initiator in amount sufficient to coagulate blood introduced into the enclosure to form a blood clot. The formed blood clot is transferable onto a wound. Method for preparing a wound dressing by introducing a volume of blood into the enclosure of the blood-clotting mold device, maintaining the blood within the enclosure for time sufficient to permit clotting of the blood to obtain a blood clot; removing the closure to open the enclosure; and extracting the blood clot from the enclosure. The formed blood clot may be used in a method for dressing a wound by fixation of the clot onto the wound.

The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.

Use of a solid calcium compound in the fabrication of a hemostatic agent for reducing bleeding from a surgical site during and/or after a surgical treatment in a patient is provided, wherein the solid calcium compound is selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, calcium oxide, calcium hydroxide, hydroxyapatite, and a combination thereof.

Compositions comprised of: (i) a blend of fibrinogen, thrombin, wherein the blend is in the form of a plurality of particles, and (ii) a hydrophobic dispersant, wherein the composition is in the form of a paste at at-least one temperature in the range of 10° C., to 37° C., are disclosed herein. Methods for preparing a fibrin adhesive sealant in/on an injured tissue are further disclosed.

The present invention relates to a process for producing a low endotoxin alkali chitosan, chitin, chitosan derivative or chitin derivative, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan, chitin, chitosan derivative or chitin derivative with an alkali solution having a concentration of less than 0.25M to form a mixture; leaving the mixture for a period of less than 12 hours and optionally drying the mixture. The low endotoxin alkali chitosan may be used in the manufacture of other useful chitosan based products.

A swellable biocompatible material and method of making the same. The material comprises a water-absorbing swellable polymer infused with povidone-iodine and a water-soluble control compound configured to control a release of iodine form the material. Example swellable polymers includes polysaccharides and hydrocolloid forming compounds.

A hemostatic surface application device having a region of hemostatic foam for contact with a patient's skin where a wound exists or is created, the device includes: a release layer, the release layer in contact with a hemostatic flexible foam section, and a structural foam layer having a front side and a back side surrounding the hemostatic flexible foam layer, forming a generally central hemostatic surface exposed through the front side of the surrounding structural foam layer, and a support layer adhered to the backside of the structural foam layer.

Disclosed herein are matrices, compositions and methods of making matrices. The matrix comprises a biomolecule and the matrix is a dried, cross-linked foam. The matrix is not lyophilized. The method comprises foaming the composition, crosslinking the composition and drying the composition. Matrices disclosed herein are useful as wound dressings and treating wounds.

A hemostatic material is described, which eliminates the risks of conventional chitosan-derived products, such as the onset of shellfish allergy and endotoxin contamination, can be used safely for more people, and has an antibacterial property and a hemostatic function that widely-used hydrogels lack, and a wound dressing containing the same. A hemostatic material containing cationized cellulose and a wound dressing containing the hemostatic are described. At least one of hydroxyl groups of the cationized cellulose is modified with —R.sup.2—N.sup.+(R.sup.3)(R.sup.4)(R.sup.5)X.sup.−, other hydroxyl groups of the cationized cellulose have —H, or —(CH.sub.2CH.sub.2O).sub.m—H, R.sup.2 represents C.sub.1-6 alkylene, C.sub.2-6 hydroxyalkylene, —(CH.sub.2CH.sub.2O).sub.1—, or a combination thereof, 1 represents 1 or 2, m represents 1 or 2, and X.sup.− may represent an anionic group.

According to the invention there is provided inter alia a process for the manufacture of a solid object having a surface comprising a layered coating of cationic and anionic polymer wherein the outer coating layer comprises an anticoagulant entity, comprising the steps of: i) treating a surface of the solid object with a cationic polymer; ii) treating the surface with an anionic polymer; iii) optionally repeating steps i) and ii) one or more times; iv) treating the surface with a cationic polymer; and v) treating the outermost layer of cationic polymer with an anticoagulant entity, thereby to covalently attach the anticoagulant entity to the outermost layer of cationic polymer; wherein, the anionic polymer is characterized by having (a) a total molecular weight of 650 kDa-10,000 kDa; and (b) a solution charge density of >4 μeq/g; and wherein, step ii) is carried out at a salt concentration of 0.25 M-5.0 M.